From 11 target genes identified in the actual study, 5 showed a differential expression at least in one comparison (e.g. JRK, SORL1, TOX4 and VPS52, which were higher abundant in the liver of patients with liver steatosis or NASH; Supplementary Table S7). This evidence concerns the gene VPS52 and metabolic dysfunction-associated steatohepatitis.